TABLE 3.
Serum anti-PRP IgG subclass concentrations at postprimary and booster time pointsa
| Study | Group | No. of subjects tested | GMC (μg/ml) (95% CI)
|
IgG1/IgG2 ratio | |
|---|---|---|---|---|---|
| IgG1 | IgG2 | ||||
| United States | |||||
| Postprimary | DTPa + HBV + OPV + Hib* | 21 | 1.83 (0.62-5.36) | 1.01 (0.59-1.72) | 1.81 |
| DTPa-HBV-IPV/Hib | 17 | 1.15 (0.56-2.37) | 0.27 (0.17-0.44) | 4.17 | |
| Postbooster | DTPa + Hib* | 33 | 17.77 (8.77-36.01) | 3.615 (2.33-5.6) | 4.91 |
| DTPa/Hib | 31 | 15.48 (7.9-30.29) | 5.09 (3.25-7.95) | 3.18 | |
| Germany B | |||||
| Postprimary | DTPa-HBV/Hib | 25 | 0.547 (0.31-0.97) | 0.213 (0.17-0.27) | 3.5 |
| DTPa-HBV + Hib | 21 | 5.204 (2.16-12.53) | 0.614 (0.36-1.04) | 8.5 | |
| Prebooster | DTPa-HBV/Hib | 25 | 0.253 (0.17-0.37) | 0.155 (0.14-0.17) | 3.0 |
| DTPa-HBV + Hib | 25 | 0.679 (0.3-1.51) | 0.182 (0.14-0.24) | 7.2 | |
| Postbooster | dtpa-HBV-PRP | 25 | 6.175 (2.34-16.3) | 1.967 (0.98-3.95) | 3.7 |
| dtpa-HBV + PRP | 21 | 21.254 (6.27-72.04) | 4.774 (2.01-11.35) | 4.5 | |
a
Not evaluated in Germany A and Myanmar studies. Blood samples were collected 1 month after the three-dose primary series and 4 to 6 weeks after the booster dose. CI, confidence interval; dtpa, experimental DTPa vaccine with reduced antigen content; OPV, oral poliovirus vaccine. *, OmniHIB.